Serum Cripto-1 is a novel biomarker for non-small cell lung cancer diagnosis and prognosis
| Autor: | Yan Wang, Qing Bo Wang, Li Hua Qian, Xiu Wei Zhang, Chunhua Xu, Li Ke Yu |
|---|---|
| Rok vydání: | 2016 |
| Předmět: |
0301 basic medicine
Pulmonary and Respiratory Medicine Oncology medicine.medical_specialty Cripto 03 medical and health sciences 0302 clinical medicine Carcinoembryonic antigen Internal medicine medicine Immunology and Allergy Clinical significance Lung cancer Genetics (clinical) Survival analysis Lung biology business.industry Hazard ratio medicine.disease 030104 developmental biology medicine.anatomical_structure 030220 oncology & carcinogenesis biology.protein Biomarker (medicine) business |
| Zdroj: | The Clinical Respiratory Journal. 11:765-771 |
| ISSN: | 1752-6981 |
| DOI: | 10.1111/crj.12414 |
| Popis: | Introduction Cripto-1 (CR-1) is highly expressed in several different types of human tumors. However, the clinical significance of CR-1 expression in serum specimens from non-small cell lung cancer (NSCLC) patients has not yet been determined. Objectives The aim of this study was to explore the diagnostic and prognostic value of serum CR-1 levels in patients with NSCLC. Methods Serum specimens from 592 NSCLC patients, 180 benign lung disease patients and 240 healthy controls were collected. The concentrations of CR-1 were measured by sandwich enzyme-linked immunosorbent assay. Results Patients with NSCLC had higher serum CR-1 levels than the controls (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|